Compare Heron Therapeutics Inc (HRTX) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Remitly Global Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Remitly Global Inc trades at $23.5 (market cap $4.85B). The key difference: Remitly Global Inc is far larger — about 65.5× Heron Therapeutics Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Remitly Global Inc for 53 Days on average.
| HRTX | RELY | |
|---|---|---|
Market Cap | $74.04M | $4.85B |
Volume | 3,668,095 | 2,599,081 |
Sector | Health | Technology |
52-Week High | $1.49 | $26.92 |
52-Week Low | $0.27 | $12.20 |
Typical Hold Time | 35 Days | 53 Days |
Enterprise Value | $180.78M | $4.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
RELY trades at $23.52, up 1.38% today, with a bullish technical signal from moving averages. The company shows strong fundamental momentum, with revenue growing from $654M in 2022 to $1.64B in 2025 and turning profitable with a net income of $67.93M. Recent Q2 2026 earnings beat expectations with EPS of $0.93 versus $0.12 expected, and active customers surpassed 10 million. Positive cash flow trends and a partnership with Etsy highlight operational strength and growth initiatives.
The outlook for RELY is positive, supported by accelerating revenue growth, expanding profit margins, and strong analyst consensus with a $30.50 price target. Key risks include reliance on continued customer expansion, competitive pressures in digital payments, and market volatility. The stock presents an opportunity for growth investors given its earnings beats and bullish institutional sentiment, though execution on growth targets remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
